Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 9:37 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 361–384 of 7,579 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Bone Clear all
Completed Phase 3 Interventional

XL TDR® eXtreme Lateral Total Disc Replacement for the Treatment of Lumbar Degenerative Disc Disease (DDD)

NCT00927238
View directory record Official record
Conditions
Degenerative Disc Disease
Interventions
XL TDR, Lumbar fusion surgery
Device · Other
Lead sponsor
NuVasive
Industry
Eligibility
18 Years to 70 Years
Enrollment
246 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
17
States / cities
Campbell, California • Thousand Oaks, California • Durango, Colorado + 14 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2015 · Synced Oct 19, 2026, 9:37 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

A Study of CFI-400945 With or Without Azacitidine in Patients With AML, MDS or CMML

NCT04730258
View directory record Official record
Conditions
Acute Myeloid Leukemia, Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, AML, MDS, CMML
Interventions
CFI-400945, Azacitidine
Drug
Lead sponsor
Treadwell Therapeutics, Inc
Industry
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
6
States / cities
Duarte, California • Sacramento, California • Louisville, Kentucky + 3 more
Source: ClinicalTrials.gov public record
Updated May 18, 2025 · Synced Oct 19, 2026, 9:37 PM EDT
Not listed Not applicable Interventional

OSTEOAMP Lumbar Fusion Intra-Patient Controlled Study

NCT05405374
View directory record Official record
Conditions
Lumbar Spine Disease, Lumbar Spondylolisthesis, Lumbar Spine Instability, Lumbar Spondylosis, Degenerative Disc Disease
Interventions
OSTEOAMP, Infuse
Other · Device
Lead sponsor
Bioventus LLC
Industry
Eligibility
21 Years to 80 Years
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
9
States / cities
New Haven, Connecticut • Wichita, Kansas • Paducah, Kentucky + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2023 · Synced Oct 19, 2026, 9:37 PM EDT
Terminated Phase 1 Interventional

Maintenance Fedratinib to Prevent Post-Transplant Relapse in Myeloproliferative Neoplasms

NCT05127174
View directory record Official record
Conditions
Myeloproliferative Neoplasm
Interventions
Fedratinib Pill
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Dec 4, 2025 · Synced Oct 19, 2026, 9:37 PM EDT
Completed Phase 2 Interventional Results available

Fungal Prophylaxis With Isavuconazole for Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant (HCT)

NCT03149055
View directory record Official record
Conditions
Hematologic Malignancy, Myeloproliferative Disorder
Interventions
Isavuconazole
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 16, 2025 · Synced Oct 19, 2026, 9:37 PM EDT
Recruiting No phase listed Observational

Caris Chromoseq Data Collection

NCT07680868
View directory record Official record
Conditions
Acute Myeloid Leukemia (AML), Myelodysplastic (MDS) / Myeloproliferative (MPN) Diseases, Myelodysplatic Syndromes, Myeloproliferative Neoplasm
Interventions
Caris Chromoseq
Diagnostic Test
Lead sponsor
Caris Science, Inc.
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Jul 2, 2026 · Synced Oct 19, 2026, 9:37 PM EDT
Not listed No phase listed Observational

Assessment of SpondyloArthritis Society (ASAS) Classification and Diagnostic Criteria for Early Axial Spondyloarthritis (SpA)

NCT00328068
View directory record Official record
Conditions
Spondyloarthritis, Spondylarthropathy, Spondylitis, Ankylosing
Interventions
Not listed
Lead sponsor
Charite University, Berlin, Germany
Other
Eligibility
18 Years and older
Enrollment
992 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 13, 2013 · Synced Oct 19, 2026, 9:37 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Evaluation of the Pathobiology of CALR-mutated MPN Cells

NCT06480591
View directory record Official record
Conditions
Myeloproliferative Neoplasm
Interventions
Blood Draw
Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
2
States / cities
Charlotte, North Carolina • Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Oct 19, 2026, 9:37 PM EDT
Active, not recruiting Phase 1 Interventional

Safety and Tolerability Study of Oral ABBV-744 Tablet Alone or in Combination With Oral Ruxolitinib Tablet or Oral Navitoclax Tablet in Adult Participants With Myelofibrosis

NCT04454658
View directory record Official record
Conditions
Myelofibrosis (MF)
Interventions
ABBV-744, Navitoclax, Ruxolitinib
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
10
States / cities
Sacramento, California • Lebanon, New Hampshire • Buffalo, New York + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2025 · Synced Oct 19, 2026, 9:37 PM EDT
Active, not recruiting No phase listed Observational

Shoulder iD™ Primary Reversed Glenoid Outcomes Clinical Study

NCT05868148
View directory record Official record
Conditions
Rotator Cuff Tears, Rheumatoid Arthritis Shoulder, Osteoarthritis Shoulder, Avascular Necrosis of the Head of Humerus, Fracture, Humeral, Traumatic Arthritis of Right Shoulder Region (Diagnosis), Shoulder Deformity
Interventions
Shoulder iD™ Primary Reversed Glenoid
Device
Lead sponsor
Stryker Trauma and Extremities
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2035
U.S. locations
5
States / cities
San Francisco, California • Columbus, Ohio • Frisco, Texas + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2026 · Synced Oct 19, 2026, 9:37 PM EDT
Completed No phase listed Observational

Prospective Clinical Assessment Study in Children With Achondroplasia (ACH)

NCT04035811
View directory record Official record
Conditions
Achondroplasia
Interventions
Not listed
Lead sponsor
QED Therapeutics, a BridgeBio company
Industry
Eligibility
30 Months to 17 Years
Enrollment
271 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
8
States / cities
Oakland, California • Aurora, Colorado • Wilmington, Delaware + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 3, 2026 · Synced Oct 19, 2026, 9:37 PM EDT
Completed Not applicable Interventional

A Study to Assess Metabolic Bone Disease of Prematurity Using an Acoustic Method

NCT04752098
View directory record Official record
Conditions
Metabolic Bone Disease, Osteopenia, Neonatal Rickets
Interventions
Vibro-acoustic analysis (VAA), based on ultrasound radiation force
Diagnostic Test
Lead sponsor
Mayo Clinic
Other
Eligibility
3 Days to 8 Months
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 27, 2025 · Synced Oct 19, 2026, 9:37 PM EDT
Completed Phase 2 Interventional Results available

A Study of Oral Recombinant Salmon Calcitonin (rsCT) to Prevent Postmenopausal Osteoporosis

NCT01292187
View directory record Official record
Conditions
Osteopenia
Interventions
Oral calcitonin at dinnertime, Oral placebo at dinnertime, Oral calcitonin at bedtime, Oral placebo at bedtime
Drug
Lead sponsor
Tarsa Therapeutics, Inc.
Industry
Eligibility
45 Years and older · Female only
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
10
States / cities
Walnut Creek, California • Clearwater, Florida • Bethesda, Maryland + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 12, 2014 · Synced Oct 19, 2026, 9:37 PM EDT
Completed Phase 2 Interventional

Campath-1H + FK506 and Methylprednisolone for GVHD

NCT00109993
View directory record Official record
Conditions
Breast Cancer, Chronic Myeloproliferative Disorders, Gestational Trophoblastic Tumor, Graft Versus Host Disease, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases, Neuroblastoma, Ovarian Cancer, Testicular Germ Cell Tumor
Interventions
alemtuzumab, methylprednisolone, tacrolimus
Biological · Drug
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
6
States / cities
New York, New York • Cleveland, Ohio • Portland, Oregon + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 11, 2010 · Synced Oct 19, 2026, 9:37 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Cinacalcet to Treat Hypercalcemia in Renal Transplant Recipients

NCT00415584
View directory record Official record
Conditions
Secondary Hyperparathyroidism, Hypercalcemia
Interventions
Cinacalcet HCl
Drug
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Apr 29, 2025 · Synced Oct 19, 2026, 9:37 PM EDT
Completed No phase listed Observational

Boston Alcohol Research Collaboration on HIV/AIDS (ARCH) Cohort

NCT01740115
View directory record Official record
Conditions
HIV Infection, Alcohol Use, Bone Disease, Substance-Related Disorders
Interventions
Not listed
Lead sponsor
Boston Medical Center
Other
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 12, 2016 · Synced Oct 19, 2026, 9:37 PM EDT
Recruiting Phase 3 Interventional

Efficacy and Safety of Novosis Putty in Transforaminal Lumbar Interbody Fusion for Patients With Lumbar Degenerative Disc Disease

NCT07017634
View directory record Official record
Conditions
Degenerative Disc Disease
Interventions
Novosis Putty, Standard of Care
Device · Other
Lead sponsor
CGBio Inc.
Industry
Eligibility
21 Years to 80 Years
Enrollment
316 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
10
States / cities
Little Rock, Arkansas • Sacramento, California • Miami, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Oct 19, 2026, 9:37 PM EDT
Completed Phase 3 Interventional Results available

Zoledronic Acid in Treating Patients With Metastatic Breast Cancer, Metastatic Prostate Cancer, or Multiple Myeloma With Bone Involvement

NCT00869206
View directory record Official record
Conditions
Breast Adenocarcinoma, DS Stage I Plasma Cell Myeloma, DS Stage II Plasma Cell Myeloma, Metastatic Malignant Neoplasm to the Bone, Pain, Musculoskeletal Complication, Urinary Complications
Interventions
zoledronic acid
Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
1,822 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
503
States / cities
Fairbanks, Alaska • Scottsdale, Arizona • Castro Valley, California + 353 more
Source: ClinicalTrials.gov public record
Updated Nov 7, 2018 · Synced Oct 19, 2026, 9:37 PM EDT
Completed Phase 2 Interventional Results available

Transplantation for Patients With Sickle Cell Disease From Mismatched Family Donors of Bone Marrow

NCT02757885
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Bone Marrow Transplant (BMT), Hydroxyurea, Thiotepa, Fludarabine monophosphate, Cyclophosphamide, Rabbit Anti-thymocyte Globulin, Total Body Irradiation
Procedure · Drug · Other + 1 more
Lead sponsor
Emory University
Other
Eligibility
15 Years to 40 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Oct 12, 2023 · Synced Oct 19, 2026, 9:37 PM EDT
Completed Not applicable Interventional Results available

Translational Development of Photon-counting CT Imaging

NCT03878134
View directory record Official record
Conditions
Cancer, Inflammatory Disease, Vascular Diseases, Metabolic Bone Disease
Interventions
PHOTON COUNTING CT Scanner
Device
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years and older
Enrollment
67 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 1, 2023 · Synced Oct 19, 2026, 9:37 PM EDT
Completed Phase 2 Interventional Results available

Efficacy Study of T Cell Depleted Allogeneic Non-myeloablative Stem Cell Transplant

NCT00597714
View directory record Official record
Conditions
Hodgkin's Disease, Non Hodgkin's Lymphoma, Myeloma, Leukemia, Myelodysplasia
Interventions
Non-myeloablative Stem Cell Transplantation
Drug
Lead sponsor
David Rizzieri, MD
Other
Eligibility
18 Years and older
Enrollment
264 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 2, 2014 · Synced Oct 19, 2026, 9:37 PM EDT
Completed Phase 2 Interventional

Chemotherapy and Bone Marrow Transplantation in Treating Patients Acute Myeloid With Leukemia or Myelodysplastic Syndrome

NCT00002547
View directory record Official record
Conditions
Leukemia, Myelodysplastic Syndromes
Interventions
busulfan, cyclophosphamide, cyclosporine, cytarabine, methotrexate, allogeneic bone marrow transplantation, syngeneic bone marrow transplantation
Drug · Procedure
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Other
Eligibility
Up to 60 Years
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1987 – 2003
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 7, 2012 · Synced Oct 19, 2026, 9:37 PM EDT
Active, not recruiting Phase 2 Interventional

A Clinical Study to Test the Effects of Ruxolitinib And Thalidomide Combination for Patients With Myelofibrosis

NCT03069326
View directory record Official record
Conditions
Myelofibrosis
Interventions
Ruxolitinib, Thalidomide
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
7
States / cities
Middletown, New Jersey • Montvale, New Jersey • Commack, New York + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Oct 19, 2026, 9:37 PM EDT
Completed Phase 1 Interventional

Aflac ST0901 CHOANOME - Sirolimus in Solid Tumors

NCT01331135
View directory record Official record
Conditions
Ewing's Sarcoma, Osteosarcoma, Astrocytoma, Atypical Teratoid/Rhabdoid Tumor, Ependymoma, Germ Cell Tumor, Glioma, Medulloblastoma, Rhabdoid Tumor, Retinoblastoma, Clear Cell Sarcoma, Renal Cell Carcinoma, Wilms Tumor, Hepatoblastoma, Neuroblastoma, Rhabdomyosarcoma
Interventions
sirolimus
Drug
Lead sponsor
Emory University
Other
Eligibility
Up to 30 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated May 29, 2020 · Synced Oct 19, 2026, 9:37 PM EDT